Histamine-2 Receptor Antagonists vs Proton Pump Inhibitors on Gastrointestinal Tract Hemorrhage and Infectious Complications in the Intensive Care Unit

被引:152
|
作者
MacLaren, Robert [1 ]
Reynolds, Paul M. [2 ]
Allen, Richard R. [3 ]
机构
[1] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Clin Pharm, Aurora, CO 80045 USA
[2] Univ Colorado Hosp, Dept Pharm, Aurora, CO USA
[3] Peak Stat Serv, Evergreen, CO USA
关键词
STRESS-ULCER PROPHYLAXIS; VENTILATOR-ASSOCIATED PNEUMONIA; COMMUNITY-ACQUIRED PNEUMONIA; SUPPRESSIVE MEDICATION USE; CRITICALLY III PATIENTS; BLEEDING PROPHYLAXIS; RISK-FACTORS; RANITIDINE; SUCRALFATE; PREVENTION;
D O I
10.1001/jamainternmed.2013.14673
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) are commonly used to prevent gastrointestinal tract (GI) hemorrhage in critically ill patients. The stronger acid suppression of PPIs may reduce the rate of bleeding but enhance infectious complications, specifically pneumonia and Clostridium difficile infection (CDI). OBJECTIVE To evaluate the occurrence and risk factors for GI hemorrhage, pneumonia, and CDI in critically ill patients. DESIGN, SETTING, AND PARTICIPANTS A pharmacoepidemiological cohort study was conducted of adult patients requiring mechanical ventilation for 24 hours or more and administered either an H(2)RA or PPI for 48 hours or more while intubated across 71 hospitals between January 1, 2003, and December 31, 2008. Propensity score-adjusted and propensity-matched multivariate regression models were used to control for confounders. MAIN OUTCOMES AND MEASURES Primary outcomes were secondary diagnoses of International Classification of Diseases, Ninth Revision (ICD-9)-coded GI hemorrhage, pneumonia, and CDI occurring 48 hours or more after initiating invasive ventilation. RESULTS Of 35 312 patients, 13 439 (38.1%) received H2RAs and 21 873 (61.9%) received PPIs. Gastrointestinal hemorrhage (2.1% vs 5.9%; P <.001), pneumonia (27% vs 38.6%; P <.001), and CDI (2.2% vs 3.8%; P <.001) occurred less frequently in the H2RA group. After adjusting for propensity score and covariates, odds ratios of GI hemorrhage (2.24; 95% CI, 1.81-2.76), pneumonia (1.2; 95% CI, 1.03-1.41), and CDI (1.29; 95% CI, 1.04-1.64) were greater with PPIs. Similar results were obtained in the propensity-matched models of 8799 patients in each cohort. CONCLUSIONS AND RELEVANCE Proton pump inhibitors are associated with greater risks of GI hemorrhage, pneumonia, and CDI than H2RAs in mechanically ventilated patients. Numerous other risk factors are apparent. These data warrant confirmation in comparative prospective studies.
引用
收藏
页码:564 / 574
页数:11
相关论文
共 50 条
  • [31] Proton pump inhibitors and histamine-2 receptor antagonists on the risk of pancreatic cancer: a systematic review and meta-analysis
    Laoveeravat, P.
    Thavaraputta, S.
    Vutthikraivit, W.
    Suchartlikitwong, S.
    Mingbunjerdsuk, T.
    Motes, A.
    Nugent, K.
    Rakvit, A.
    Islam, E.
    Islam, S.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2020, 113 (02) : 100 - 107
  • [32] Proton pump inhibitors vs Histamine-2 receptor antagonists and risk of mortality in critically ill patients - a pilot analysis of multi-institutional study
    Hsieh, Hsing-Chun
    Lin, Tsung-Hsuan
    Lee, Mei-Chuan
    Su, Hui-Chen
    Shao, Shih-Chieh
    Su, Chien-Chou
    Lai, Edward Chia-Cheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 577 - 578
  • [33] Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia
    Marshall, JK
    Grootendorst, PV
    O'Brien, BJ
    Dolovich, LR
    Holbrook, AM
    Levy, AR
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2002, 166 (13) : 1655 - 1662
  • [34] Risk of clostridium difficile infection associated with used of proton pump inhibitors and histamine-2 receptor antagonists in Taiwan hospitalized patients
    Liu, Yi Hsuan
    Yang, Yea-Huei Kao
    Wu, Lu Hsuan
    Su, Chien-Chou
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 273 - 273
  • [35] Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies
    Liu, Peipei
    McMenamin, Una
    Johnston, Brian
    Murchie, Peter
    Iversen, Lisa
    Lee, Amanda
    Vissers, Pauline
    Cardwell, Christopher
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 45 - 45
  • [36] Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: A cost-effectiveness analysis
    Harris, RA
    Kuppermann, M
    Richter, JE
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1997, 92 (12): : 2179 - 2187
  • [37] Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies
    Peipei Liu
    Úna C. McMenamin
    Brian T. Johnston
    Peter Murchie
    Lisa Iversen
    Amanda J. Lee
    Pauline A. J. Vissers
    Chris R. Cardwell
    British Journal of Cancer, 2020, 123 : 307 - 315
  • [38] Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies
    Liu, Peipei
    McMenamin, Una C.
    Johnston, Brian T.
    Murchie, Peter
    Iversen, Lisa
    Lee, Amanda J.
    Vissers, Pauline A. J.
    Cardwell, Chris R.
    BRITISH JOURNAL OF CANCER, 2020, 123 (02) : 307 - 315
  • [39] No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014)
    Landi, Suzanne N.
    Sandler, Robert S.
    Pate, Virginia
    Lund, Jennifer L.
    GASTROENTEROLOGY, 2018, 154 (04) : 861 - +
  • [40] Histamine-2 receptor antagonists at night improve GERD symptoms for patients on proton pump inhibitor therapy
    Rackoff, A
    Agrawal, A
    Hila, A
    Mainie, I
    Tutuian, R
    Freeman, J
    Castell, DO
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S18 - S18